Digihost Technology Inc. DGHI
Set alert
At close · Mar 17
52-week range unavailable
- Open
- 1.23
- Prev close
- 1.32
- Mkt cap
- 46.88M
- Vol
- 169.91K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.16
- High
- 1.33
- Forward P/E
- -1.93
- Beta
- 7.21
- Short ratio
- 1.47
- Inst. own
- 10.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.71
- 200-d avg
- 1.41
- 1y target
- 2.50
News
-
3 years ago benzinga.com
Why Asbury Automotive Group Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
OnFriday, 143 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 529 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 539 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 340 companies made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows.
-
4 years ago benzinga.com
52 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969.
-
4 years ago benzinga.com
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of sBCC with Ameluz-PDT.